Skip to Main Content

Author Details

Massimo Loda
Weill Medical College of Cornell University
1984
470
117
PMIDPaper TitleJournal TitlePublished Year
37659962Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.Eur Urol2024
36256912Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.J Clin Oncol2023
37721526Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis.Clin Cancer Res2023
37555839Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.Cancer Epidemiol Biomarkers Prev2023
37581614SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.Clin Cancer Res2023
37502956NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.bioRxiv2023
37334024PI-RADS 3 score: A retrospective experience of clinically significant prostate cancer detection.BJUI Compass2023
37134151Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer.Sci Transl Med2023
37034687Distinct mesenchymal cell states mediate prostate cancer progression.bioRxiv2023
37292972Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.bioRxiv2023
36401094Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.J Cancer Res Clin Oncol2023
36511902The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.Mol Cancer Res2023
36482187"Stromal cells in prostate cancer pathobiology: friends or foes?"Br J Cancer2023
36126301A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.Blood2023
36125519Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.Mol Cancer Res2023
35164752O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.J Biomed Sci2022
35584006Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.Cancer Res2022
35507982Fatty acid synthase as a potential new therapeutic target for cervical cancer.An Acad Bras Cienc2022
35731919The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Cancer Res2022
35490048A multidisciplinary approach to optimize primary prostate cancer biobanking.Urol Oncol2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36139519Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine.Cancers (Basel)2022
36358940Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.Biomolecules2022
36325690The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Mol Cancer Ther2022
36325685The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Mol Cancer Res2022
36321301The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Cancer Epidemiol Biomarkers Prev2022
36321298The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Cancer Immunol Res2022
36321294The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Blood Cancer Discov2022
36321264The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Cancer Res2022
36317374The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Clin Cancer Res2022
36317369The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.Cancer Prev Res (Phila)2022
35253958Intra-epithelial non-canonical Activin A signaling safeguards prostate progenitor quiescence.EMBO Rep2022
34880124Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology.Mol Cancer Res2022
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35105671Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.Mol Cancer Res2022
32986884Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.Prostate2021
35474657Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.BJUI Compass2021
33627383Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes.Cancer Epidemiol Biomarkers Prev2021
33547161ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.Cancer Res2021
33712587Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions.Nat Commun2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
33758858Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps.bioRxiv2021
33500320Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.Cancer Epidemiol Biomarkers Prev2021
34939926Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.Elife2021
34592899Inhibition of CDK9 activity compromises global splicing in prostate cancer cells.RNA Biol2021
34560002PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis.Mol Cell2021
34099734Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.Nat Commun2021
34013020The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic.Acad Pathol2021
34344464Inflammatory metabolic profile of South African patients with prostate cancer.Cancer Metab2021
  • 1 - 50 of 470

Recommended Authors

Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 24
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 43
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 63
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Career Start Year 2005
Number of shared co-authors 45
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 21
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 32
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 40
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 29
H??l??ne Hovington
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1999
Number of shared co-authors 23
Leena Latonen
Foundation for the Finnish Cancer Institute
Career Start Year 1999
Number of shared co-authors 2
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 6
Hal K Berman
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1997
Number of shared co-authors 4
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1996
Number of shared co-authors 20
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 59
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 39
Michael R Emmert-Buck
The Francis Crick Institute
Career Start Year 1994
Number of shared co-authors 13
Anirban Maitra
The University of Texas MD Anderson Cancer Center
Career Start Year 1993
Number of shared co-authors 30
Bhaskar Kallakury
Georgetown University
Career Start Year 1993
Number of shared co-authors 5
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 23
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 56
Nora M Navone
MD Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 31
Beatrice S Knudsen
University of Utah
Career Start Year 1986
Number of shared co-authors 55
Dean A Troyer
Eastern Virginia Medical School
Career Start Year 1985
Number of shared co-authors 20
Olli Kallioniemi
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 22
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 37
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Career Start Year 1979
Number of shared co-authors 88
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 71
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 5
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 32

Collaborators

Lorelei A Mucci
Co-authored papers 68
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 49
Rosina T Lis
National Cancer Institute
Co-authored papers 43
Edward L Giovannucci
Harvard T.H. Chan School of Public Health
Co-authored papers 41
Meir J Stampfer
Brigham and Women's Hospital
Co-authored papers 33
Kathryn L Penney
Co-authored papers 31
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Co-authored papers 22
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Co-authored papers 19
Mark A Rubin
University of Bern
Co-authored papers 17
William R Sellers
Co-authored papers 17
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 16
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 16
Myles Brown
Co-authored papers 16
Michaela Bowden
Dana-Farber Cancer Institute
Co-authored papers 15
Phillip G Febbo
Illumina Inc.
Co-authored papers 14
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 14
Lewis C Cantley
Co-authored papers 14
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 13
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 11
Brian D Robinson
Sandra and Edward Meyer Cancer Center
Co-authored papers 11
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 11
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 10
Jing Ma
Co-authored papers 10
Azra H Ligon
Co-authored papers 10
Thomas J George
UF Health Cancer Center
Co-authored papers 9
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 9
William K Oh
Co-authored papers 9
Matthew Meyerson
Broad Institute
Co-authored papers 8
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 8
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Release 1.2